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Edited by Hans-Dieter KlenkAbstract The non-structural protein 3 (NS3) of hepatitis C
virus (HCV) is a highly promising target for anti-HCV therapy
because of its multiple enzymatic activities, such as RNA-
stimulated nucleoside triphosphatase, RNA helicase and serine
protease. The helicase domain of NS3 as well as domain 2 of the
helicase were expressed in a baculovirus system to obtain in high
yield active proteins for prospective studies of complexes of the
helicase with its inhibitors. A novel direct ﬂuorometric test of
helicase activity with a quenched DNA substrate, 3
0
labeled with
a Cy3 dye and 5
0
labeled with a Black Hole Quencher, was
developed and optimal reaction conditions established. This test
based on ﬂuorescence resonance energy transfer is simple and
fast. It allows for direct measurements of enzyme activity,
circumventing laborious and complicated radioactive techniques
that are poorly reproducible. The results obtained encourage us
to propose this new ﬂuorescent assay as a method enabling high
throughput screening of anti-helicase compounds.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hepatitis C virus (HCV) is a single-stranded (+) RNA virus
of the Hepacivirus genus in the Flaviviridae family. Its genome
of 9600 nucleotides encodes a polyprotein of 3000 amino
acids that is co- and post-translationally cleaved into 10 ma-
ture proteins. Three have structural functions (C, E1, E2), and
one (p7) is a membrane protein possibly involved in virion
release and maturation [1,2]. The non-structural proteins in-
clude NS2 (metallo/thiol protease), non-structural protein 3
(NS3) (serine protease/RNA helicase), NS4A (serine protease
cofactor), NS4B (unknown function), NS5A (role in replica-
tion and resistance to interferon-a), and NS5B (RNA-depen-
dent RNA polymerase).* Corresponding author. Fax: +48-22-658-46-36.
E-mail address: annach@ibb.waw.pl (A.M. Boguszewska-
Chachulska).
Abbreviations: BHQ, Black Hole Quencher; fu, ﬂuorescence units;
HCV, hepatitis C virus; NS3, non-structural protein 3; NTPase,
nucleoside triphosphatase
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doi:10.1016/j.febslet.2004.04.072HCV represents a serious worldwide epidemiological threat,
infecting up to 3% of the population. Chronic hepatitis re-
sulting from HCV infection develops in most cases into cir-
rhosis and highly increases the risk of hepatocellular
carcinoma [3]. No vaccine for HCV has been developed to date
in spite of numerous attempts [4–6]. No eﬃcient treatment
exists; even the new dual therapy with pegylated interferon and
ribavirin is eﬀective only in up to 56% of the cases, depending
on the genotype of the virus and duration of treatment [7].
The most promising target for anti-HCV therapy seems to be
NS3 because of its multiple enzymatic activities. The helicase
activity is indispensable for viral replication [8], presumably
unwinding double-stranded replication intermediates and sec-
ondary structures, allowing RNA ampliﬁcation [1]. Recent data
demonstrate thatNS3 can interactwithNS4BandNS5B to form
a complex modulating template recognition by NS5B [9]. NS3
may also inﬂuence the type of host response to HCV infection
and could serve to prepare DNA vaccines against HCV [6].
The HCV helicase activity can be measured using diﬀerent
techniques, the most widely applied being a radioactive test,
initially developed for the NS3 helicase by Kim et al. [10], and
since then applied by others [11–14] who characterized the







overhang to start unwinding and dsDNA helicase activity.
The enzyme has a higher aﬃnity for dsDNA than for dsRNA
and requires the NS4A cofactor for full activity on RNA [15].
In spite of its high sensitivity (the dsDNA template con-
centration may be as low as a few pM; [16]), the radioactive
test has some disadvantages, especially the tedious preparation
and instability of the radiolabeled substrate [13]. Moreover, it
is not a simple direct measurement of enzyme activity since the
reaction products must be separated by gel electrophoresis and
then submitted to further analyses, i.e., visualization by au-
toradiography and quantiﬁcation, that leads to a low repro-
ducibility of ﬁnal results. Therefore, considerable work was
performed to establish high throughput methods. This resulted
in three types of assays, two involving radioactivity and signal
ampliﬁcation by scintillation (scintillation proximity assay [17]
and the FlashplateTM assay [18]), and one ELISA-based assay
[19,20]. The latter test avoids radioactivity but is slow; in ad-
dition, neither this nor the former methods allow to follow
directly the helicase activity.
Our objective was to develop a fast non-radioactive high
throughput assay to easily and directly assess enzyme activity,
and measure the inhibitory potential of diﬀerent HCV helicase
inhibitors in a microtitration plate-format test. We chose toblished by Elsevier B.V. All rights reserved.
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energy transfer (FRET) phenomenon ([21–23], J. George
(Amersham Biosciences), personal communication) to create
such a method involving a newly introduced ﬂuorescence
quenching molecule (Black Hole Quencher, BHQ, Biosearch
Technologies).
Here, we describe the expression and puriﬁcation of the
HCV helicase and its domain 2, and the development and
optimization of the new helicase assay.2. Materials and methods
2.1. Cloning and expression of the HCV helicase and its domain 2
The Bac-to-Bac baculovirus expression system (Gibco BRL) was
chosen to construct a recombinant baculovirus. The helicase cDNA
(coding for amino acids 1193–1658 of the HCV-1 isolate (Acc. No.
AAA45676)) [10] was cloned in the pFastBacHTb vector using the
BamHI and HindIII cloning sites. After sequencing, the termination
codon from the original construct lost during cloning was restored by
inserting a self-annealed oligonucleotide (AGCTCTCTAGAG) into
the HindIII site. Transposition to a bacmid (bMON14272), transfec-
tion of SF21 insect cells and ampliﬁcation of the recombinant virus
were done according to the Gibco BRL manual. The HCV helicase,
located downstream of the polyhedrin promotor of AcMNPV and
carrying an N-terminal His-tag, was expressed in the High Five (HF)
insect suspension cell culture.
Domain 2 (amino acids 1352–1509 of the HCV-1 isolate) was cloned
in the pFastBacHTa vector by PCR ampliﬁcation using the sense
(TTGGAATTCCCGGGCTCCGTCACTG) and the antisense (AAA-
AAAGCTTGGGCGCTCCCCCGGTG) primers and the HCV-1
cDNA template, and subsequent cleavage with EcoRI and HindIII of
the PCR product and the vector. After transposition of the domain 2
coding sequence to the bacmid, the recombinant virus was transfected
into SF21 insect cells for ampliﬁcation and the protein with an N-
terminal His-tag was expressed in HF insect cells.
2.2. Puriﬁcation of the HCV helicase
HF insect cells were infected with the recombinant baculoviruses at a
multiplicity of infection of 1, they were propagated as a suspension cell
culture in Express Five SFM (Invitrogen) medium, and harvested 44–
48 h post-infection (h.p.i.).
The standard helicase and domain 2 puriﬁcation protocol, calculated
for 50 ml of infected insect cell culture (1 108 cells), included cen-
trifugation for 10 min at 720 g at 4 C and resuspension of the cells in
5 ml of buﬀer A (20 mM Tris–HCl, pH 7.0, 500 mM NaCl, and 5 mM
imidazole) supplemented with protease inhibitor cocktail (Complete,
EDTA-free, Roche). The cells were frozen in liquid nitrogen, brought
to 37 C and vortexed; freezing and thawing were repeated ﬁve times.
The suspension was centrifuged twice at 20 000 g at 4 C for 15 min.
Subsequently, glycerol was added to the clear supernatant to 10% and
CHAPS to 0.05%, the extract was mixed with 0.5 ml of Talon Metal
Aﬃnity Resin (Clontech) washed previously with 3 ml of buﬀer A, and
left overnight on a rocking platform at 4 C, or 2–3 h on ice. The
mixture was washed four times with 3–4 ml of buﬀer B (buﬀer A with
10% glycerol and 0.05% CHAPS), then three times with 3–4 ml of
buﬀer A. Three to ﬁve elutions with 0.5 ml of buﬀer E (20 mM Tris–
HCl, pH 7.0, 200 mM NaCl, and 200 mM imidazole) were performed.
If needed, helicase anddomain 2 eluateswere concentrated onAmicon
Ultra ﬁlters 30 000 and 10 000 MWCO (Millipore), respectively. They
were diluted 2-fold with 20 mMTris–HCl, pH 7.0, and applied onto a 1
ml Heparin HP column (Amersham Biosciences). The column was wa-
shed with 10 ml of buﬀer C (20 mM Tris–HCl, pH 7.0, and 100 mM
NaCl). Since the helicase does not bind to heparin and domain 2 binds to
heparin only very weakly, wash fractions were collected, concentrated
on AmiconUltra ﬁlters, and stored in 20% glycerol at )20 C. Before re-
utilization, the columnwas washed with buﬀer D (20 mMTris–HCl, pH
7.0, and 1MNaCl). Concentrations ofHCVhelicase and domain 2were
determined at 280 nm using molar extinction coeﬃcients of 51 760 and
11 760 M1 cm1, respectively. The extinction coeﬃcients were calcu-
lated on the basis of protein composition by the ProtParam program
from the Expasy website (http://us.expasy.org).2.3. Protein analysis
Extracts and eluates were analyzed by 12% SDS–PAGE and proteins
visualized by Coomassie staining or electrotransferred onto an Opti-
tran BA-S 85 membrane (Schleicher and Schuell). Helicase and domain
2 were detected with HCV-positive human antiserum, followed by
addition of a goat anti-human IgG(H+L)-alcaline phosphatase con-
jugate (Bio-Rad) as the secondary antibody. The proteins were re-
vealed colorimetrically using chromogenic substrates (NBT/BCIP
Solution, Roche).
Rabbit polyclonal anti-HCV helicase and anti-Potato virus Y (PVY)
coat protein antibodies were obtained at the Veterinary Institute,
Puławy.
2.4. ATPase assay
The ATPase assay was performed essentially as described [24]. Re-
actions were carried out in 12.5 ll of reaction buﬀer for 60 min at 30 C,
stopped by addition of 250 ll of activated charcoal, centrifuged, and
duplicate 25 ll samples of the supernatant were Cerenkov counted.
2.5. Fluorescent helicase assay
The substrate for the ﬂuorescent helicase test was prepared by
annealing at a 1:1.2 molar ratio, a 5
0
Cy3-labeled 36-mer (TAG-
TACCGCCACCCTCAGAACCTTTTTTTTTTTTTT) to a 3
0
BHQ-
2-labeled 22-mer (GGTTCTGAGGGTGGCGGTACTA), both
HPLC-puriﬁed (metaBIOn, Germany) in 20 mM Tris–HCl, pH 7.5, by
brief heating to 90 C, then slow cooling to room temperature. Stan-
dard helicase assays were performed in 30 mM Tris–HCl, pH 7.5, 5
mM MgCl2, 0.075% Triton X-100, 0.05% sodium azide, 20 nM sub-
strate, 1 mM ATP and 250 nM capture strand (TAGTACCGC
CACCCTCAGAACC). The unwinding reaction was started by addi-
tion of HCV helicase (2–20 nM) or ATP and was carried out at 37 C
for up to 90 min. The ﬂuorescent signal increase was measured using
either a Fluorescence Reader FLx (Biotek) or a ﬂuorescent spectro-
ﬂuorometer FluoroMax (Spex). The reaction volume was 200 ll for the
FLx (in a 96-well microtiter plate) and 500 ll for the Spex ﬂuorometer
(in a single cuvette). The ﬂuorescent signal was registered every 300 s
(FLx) or 30 s (Spex). Since the excitation maximum for the Cy3 ﬂu-
orophore is 550 nm and the emission maximum is 570 nm, the ﬂu-
orophore was excited at 550 nm and helicase activity was measured at
570 nm (Spex), or at 620 nm (FLx), i.e., not at the main maximum but
still within the range of the second emission maximum.
The enzyme activity was calculated as the initial reaction velocity
from the linear part of the progress curve using the linear regression
method. A linear equation Y ¼ Aþ BX was ﬁtted to experimental
data, where Y is the enzyme activity expressed in ﬂuorescence units
(fu), X is the reaction time and B is the slope or the initial velocity. The
Origin 6.1 program (OriginLab Corporation) was used to calculate the
data.3. Results
3.1. Overexpression and puriﬁcation of the HCV helicase and its
domain 2
The helicase domain of the HCV NS3 protein is composed
of three separate structural domains, domain 1 containing
nucleoside triphosphatase (NTPase) motifs, domain 2 with
several conserved motifs, among them an arginine-rich
sequence possibly involved in RNA or ATP binding, and
domain 3 without conserved motifs [25,26]. Using NMR
spectroscopy, binding of inhibitors to the entire helicase can be
detected [27], after which individual domains can be studied
separately to precisely locate sites of interaction.
We decided to validate the new helicase assay by compara-
tive studies of the full-length helicase and its domain 2 that
may hypothetically exert some of the HCV helicase functions.
Both constructs were expressed as N-terminal His6-tagged
fusion proteins and puriﬁed from HF cells collected 48 h.p.i.
when the level of protein expression was the highest without
signiﬁcant degradation. In the cell lysates, proteins of the ex-
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sequent Western blots (Fig. 1A). Non-denaturing cell lysis was
followed by native puriﬁcation on Talon Resin and the pro-
teins further puriﬁed on a Heparin HP column; 95% purity was
reached as estimated by SDS–PAGE and Coomassie staining
(Fig. 1B). The identity and size of the proteins were conﬁrmed
by mass spectrometry; their molecular masses were 53.3 and
21.5 kDa, respectively.
The proteins were puriﬁed in high yield, 15 mg l1 for the
helicase and 20 mg l1 for domain 2, their purity and yield
amenable for NMR and crystallization studies (in progress).
3.2. ATPase activity of the HCV helicase
The ATPase activity of the puriﬁed proteins was measured:
it was 49-fold higher for the full-length protein than for do-Fig. 1. Expression and puriﬁcation of HCV helicase proteins. (A)
Western blot analysis of the helicase and domain 2 expression in HF
insect cells. Lane 1, uninfected cells; lane 2, prestained molecular
marker (SM0441, Fermentas); lane 3, cells infected with recombinant
virus carrying the full-length helicase gene; lane 4, cells infected with
recombinant virus carrying domain 2 gene; lane 5, puriﬁed full-length
helicase; lane 6, puriﬁed domain 2. (B) Enzyme puriﬁcation analyzed
by SDS–PAGE and detected by Coomassie staining. Lane 1, cells
expressing the full-length helicase; lane 2, eluate from Talon column;
lane 3, eluate from Heparin column; lane 4, prestained molecular
marker (SM0441, Fermentas); lane 5, cells expressing domain 2; lane 6,
domain 2 eluted from Heparin column.main 2 (10 182 436 and 208 293 cpm/pmol, respectively).
The activity of domain 2 was insigniﬁcant, being only slightly
higher than that of prolactin, a puriﬁed control protein with-
out NTPase motifs, expressed in the insect cells [28].
3.3. Fluorescent HCV helicase assay
In the new assay established here, a quenched duplex DNA
substrate with a 3
0
single-strand overhang was obtained by
annealing two oligonucleotides, a 5
0
Cy3-labeled 36-nucleotide
donor and a 3
0
BHQ-2-labeled 22-nucleotide quencher. Fluo-
rescence emitted by the cyanine dye (550–650 nm) is quenched
due to FRET or contact-mediated quenching between the cy-
anine donor and the quencher when the molecules are sepa-
rated by 10–100 A [21,22]. The quenching maximum of BHQ-2
is 579 nm, it belongs to ‘‘true dark quenchers’’ with much
higher signal-to-noise ratios than other quencher dyes (DAB-
CYL and TAMRA) [22]. Fluorescence emission results from
the helicase activity that separates the strands leading to the
arrest of FRET. The addition of excess capture strand (com-
plementary to the quencher oligonucleotide) is crucial because
it prevents reannealing of the unwound duplex and dramati-
cally increases the reaction eﬃciency.
The main objective of this work was to deﬁne the optimal
parameters of the HCV helicase assay; ﬁrst the optimum en-
zyme, substrate and capture strand concentrations were de-
termined, then the optimum temperature, pH, ATP
concentration, and cation type and concentration, always us-
ing the standard helicase reaction conditions. Initial velocities
of helicase reactions were calculated as described in Section 2.
Reactions were carried out for 15–90 min but for calculations
only the linear parts of the slopes were used. Any discrepancies
from standard reaction conditions are mentioned in the ﬁgure
legends.
A linear dependence of the enzyme activity as a function of
incubation time was observed up to 10 min, then much before
the activity reached its maximum, increase of activity was no
longer linear (Fig. 2) and even some decrease in enzyme ac-
tivity was observed after 60–90 min (data not shown), due
probably to establishment of a steady-state equilibrium, sub-
strate exhaustion and slow degradation of both enzyme and
substrate. However, we observed no signiﬁcant decrease of theFig. 2. Typical time-course of the helicase reaction studied using the
Spex ﬂuorometer. The ﬂuorescent signal was measured every 30 s.
Triangles: with 20 nM enzyme; circles: without enzyme.
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as control in the helicase assay. In the absence of helicase, no
signiﬁcant ﬂuorescence signal increase was observed (Figs. 2
and 3). Almost linear dependence of reaction velocity on en-
zyme concentration was observed up to 20 nM (Fig. 3). Even
at helicase concentrations as low as 2 nM, the reaction was
suﬃciently eﬃcient to study the inﬂuence of inhibitors.
The inﬂuence of substrate concentration from 0 to 160 nM
on the reaction velocity was investigated (Fig. 4) at a capture
strand to substrate molar ratio of 12.5–1. No substrate inhi-
bition was observed, as opposed to results obtained with ra-
dioactive helicase assays where non-saturating substrate
concentrations were required [29,30]. Without capture strand
the reaction was practically stopped (not shown), probably
because of immediate reannealing of the separated strands.
The reaction velocity increased linearly with capture strand
concentration up to 250 nM, i.e., at 12.5:1 capture
strand:substrate ratio.
The optimum temperature for the reaction was 37 C, re-
action velocities were lower at 25 and 30 C (reaching 58% and
77% of the value at 37 C, respectively).Fig. 3. Eﬀect of HCV helicase concentration on the rate of unwinding.
These experiments were repeated ﬁve times. The data are presented as
meansS.E.
Fig. 4. Substrate dependence of the helicase reaction (20 nM enzyme).
Substrate titration was carried out in triplicates. The data are pre-
sented as meansS.E.The eﬀect of ATP concentration was studied using two ap-
proaches. The ﬁrst was to increase the Mg2þ concentration
with the ATP concentration (Fig. 5A), maintaining a 5:1 molar
ratio. No unwinding was observed in the absence of ATP and/
or divalent ions (Fig. 5A and B) conﬁrming the catalytical
mode of action of the enzyme [31]. The highest enzyme activity
was reached at 2.5 mM ATP and 12.5 mM MgCl2 with an
abrupt decrease at higher ATP concentrations. The Km value
for ATP was 0.78 0.09 mM. The second type of experiment
consisted in changing only the ATP concentration, maintain-
ing 5 mM MgCl2 (not shown): the optimum helicase activity
was observed at 1 mM ATP with an inhibitory eﬀect at higher
ATP concentrations (Km ¼ 0:33 0:002 mM).
Relative ATP/MgCl2 concentrations seem very important,
probably because Mg2þ and ATP bind as a complex to ATP-
binding enzymes [32]. At limiting Mg2þ concentrations, ATP
molecules were probably not suﬃciently coordinated by di-
valent ions.
We determined the optimal concentration and type of ions
required at 1 mM ATP (Fig. 5B). The helicase activity reached
a maximum at 5 mM Mg2þ and decreased at higher Mg2þFig. 5. Eﬀect of ATP and divalent ion concentration on the helicase
reaction velocity (20 nM enzyme). (A) ATP-dependence. The Mg2þ
concentration was 5-fold higher than the ATP concentration. Deter-
mination of optimal ATP concentration was repeated ﬁve times. The
data are presented as means S.E. (B) Inﬂuence of Mg2þ (triangles)
and Mn2þ (circles) concentrations on unwinding. All data are means of
ﬁve experimentsS.E.
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Surprisingly, at 6 7.5 mM Mn2þ, the helicase exhibited lower
activity than at identical Mg2þ concentrations, but at 10 mM
Mn2þ the reaction velocity still increased, suggesting that to
reach optimal conditions, 10 mM Mn2þ should be used. Dis-
crepancies exist between the results of diﬀerent authors con-
cerning optimum divalent ion type and concentration, and in
some studies a certain bias of the enzyme for Mg2þ was
demonstrated [10]. This may depend not only on the concen-
tration of divalent ions used [13] but possibly also on the type
of assay and substrate (RNA or DNA) as in the FlashPlate
assay involving a DNA substrate [18] in which Mn2þ was more
eﬃcient than Mg2þ at concentrations >0.25 mM.
The eﬀect of pH between 6.5 and 9.5 on the reaction rate was
examined. Lower pH values were not examined to avoid un-
speciﬁc increase of ﬂuorescence signal that occurred in these
conditions; pH 6.5 seems optimal (not shown).
Based on these experiments, the optimal reaction conditions
are: 2.5 mM ATP, 10 mM MnCl2, and 30 mM Tris–HCl, pH
6.5 (with 0.075% Triton X-100, 0.05% sodium azide, 20 nM
substrate, and 250 nM capture strand, at 37 C). These con-
ditions resulted in the highest reaction velocity (up to 6-fold
higher than in the standard conditions, described in Section 2).
This test was veriﬁed with various helicase preparations, also
overexpressed in organisms other than insect cells. The NS3
helicase puriﬁed from Escherichia coli using the native protocol
established for the baculovirus protein was equally active in
the helicase assay in contrast to preparations obtained using
denaturing methods (not shown).
The activity of highly puriﬁed domain 2 of the helicase
compared to the activity of the entire protein was insigniﬁcant,
being 350-fold lower than that of the full-length protein, while
the control protein (prolactin) demonstrated no activity (not
shown).
Preincubation of the helicase with the substrate (with ATP
added to start the reaction at the end of preincubation) mod-
erately increased the rate of unwinding. Whereas the reaction
velocity without preincubation was 19.5 1.4 fu/min, after 10
min of preincubation at room temperature it increased to
26.0 7.6 fu/min, a velocity increase of 33%. A longer prein-
cubation (30 min) had a much lower or even negative eﬀect on
enzyme activity, probably due to decreased enzyme stability at
room temperature in the absence of ATP.
Inhibition of enzyme activity was observed in the presence of
anti-HCV helicase antibodies, using antibodies against PVY
coat protein (also carrying a His-tag) as negative control.
Enzyme activity (compared to enzyme incubated without an-
tibodies) was reduced in both samples, 9- and 5-fold with the
speciﬁc and the non-speciﬁc antibodies, respectively; this low
diﬀerence in the inhibition level could be due to the presence of
a certain level of anti-His antibodies in both sera. Potassium
ions (200 mM), shown previously to inhibit the helicase ac-
tivity [13,19], decreased the unwinding eﬃciency to 13.5%.4. Discussion
Searching for a suitable system to screen a variety of possible
HCV helicase inhibitors, and to prepare material for NMR
and crystallization studies of complexes of this enzyme with
selected inhibitors, the entire helicase and its central domain 2were overexpressed in a baculovirus system. This approach
was chosen to avoid problems with low solubility and yield of
proteins expressed in E. coli that makes their puriﬁcation in
active form diﬃcult. The yield and purity of the full-length
helicase and domain 2 make them suitable for structural and
enzymatic studies as demonstrated here.
A helicase assay was developed to enable high throughput
screening of helicase inhibitors. One of the main advantages of
this test is its rapidity: even 15 min after the start of the re-
action, the results can be analyzed, helicase activities of various
samples compared, conditions modiﬁed, and a new test initi-
ated. This is a simple and rapid test, the only limitation being
access to a ﬂuorometer. The test is sensitive because 2 nM
helicase and 10 nM substrate are suﬃcient to study the inﬂu-
ence of various chemical compounds on enzyme activity as
compared to other methods that require 10–100-fold higher
enzyme concentrations [14,16,19,33]. The helicase reaction
belongs to relatively ineﬃcient reactions and in most assays a
large excess of helicase over substrate is required, even as high
as 20 nM helicase versus 4.7 pM substrate because of substrate
inhibition [16]; in these conditions, the helicase acts in a stoi-
chiometric, non-catalytic manner as opposed to our assay
where this is avoided by adding excess capture strand; enzyme
concentrations may be lower than those of the substrate, better
mimicking normal replication conditions. It should also be
stressed that no toxic compounds and waste products are
produced, and the ﬂuorescent substrate is stable for at least
one year at )80 C.
This type of assay may have some limitations due to auto-
ﬂuorescence of certain compounds submitted to tests but this
problem may be partially solved using various ﬂuorophores
and appropriate sets of excitation/emission ﬁlters selected on
the basis of the autoﬂuorescence spectrum. In addition, in each
test, the background is measured and the ﬁnal results are
corrected by subtraction of the background value. We have
already tested another pair of ﬂuorophore/quencher (FAM/
BHQ-1) and applied it successfully to test the inhibitory eﬀect
of autoﬂuorescent epirubicin [an anthracycline cytotoxic agent
(the 4
0
-epimer of doxorubicin), used widely in cancer therapy]
on the HCV helicase activity (to be published elsewhere).
Both helicase and ATPase assays conﬁrmed that signiﬁcant
enzymatic activity is observed only with the full-length heli-
case, domain 2 showing only residual ATPase activity. Do-
main 2 does not contain canonical NTPase motifs, although
binding of ATP-Mg2þ is believed to occur in the cleft between
domains 1 and 2, and a conserved arginine-rich sequence in
domain 2 may be involved in this reaction [16,25]. Newly
identiﬁed motifs in domain 2, an Arg-clamp and a Phe-loop,
are critical for DNA/RNA binding and substrate unwinding
[33]. Moreover, a second nucleoside/nucleotide binding site
[16,34] could be located in domain 2 and be responsible for the
residual ATPase activity detected.
Using the present assay, we have demonstrated that two
other putative helicases overexpressed in E. coli, those of PVY
and Saccharomyces cerevisiae Ja2, possess DNA helicase ac-
tivity although lower than that of the HCV NS3 protein in the
conditions established for the ﬂavivirus protein (to be pre-
sented elsewhere). Thus, this assay could serve to study heli-
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